Beyond defining a mitochondrial mechanism for fuel switching, this work provides a conceptual landscape for future investigation of metabolic adaptation across diverse physiological contexts, including exercise, distinct fasting paradigms, and hormone-driven metabolic regulation, and offers new insight into the determinants of responsiveness to GLP1R agonist-based anti-obesity therapies
Consequently, it seems there are important combinations of distinct signaling properties to the biased agonism of TZPD, which further may account for the promising efficacy of TZPD in damaged cells including cardiomyocytes
Together they aim to cover fat metabolism, systemic signaling, and direct tissue repair
What they're saying: "Over the past year, weve been actively driving change in the GLP-1 weight management space to help lower costs," CVS Caremark said in a news release
We look forward to seeing further results as this may suggest a path forward for semaglutide as part of a combination therapy approach. 5